Merck & Co., Inc. (MRK)

79.98
NYSE
Prev Close 80.75
Day Low/High 79.24 / 81.52
52 Wk Low/High 68.38 / 91.40
Exchange NYSE
Shares Outstanding 2525.94B
Market Cap 203.97B
P/E Ratio 17.80
Div & Yield N.A. (N.A)

Latest News

Omicron, Biden, Market Rally, Covid Fighting Pills, Trading Apple

Omicron, Biden, Market Rally, Covid Fighting Pills, Trading Apple

Perhaps the rally had been set up by the depth of the pressure placed on financial markets over the prior three days. Perhaps.

Merck Cut at UBS

Let's Check Up on 2 Immunology-Focused Oncology ETFs

Let's Check Up on 2 Immunology-Focused Oncology ETFs

Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.

A Little This, a Little That

Looking at the top five in the DJIA: * American Express breaches its 20-day moving average ($174.93) * Salesforce back to the mid-$260s after a big spill * Intel is gapping above its 50-day moving average ($51.13) after the announcement of its plan ...

Should Investors Believe in Bounces as Markets Get Choppy?

Should Investors Believe in Bounces as Markets Get Choppy?

Sector selection will remain paramount as pandemic effects continue to permeate.

Merck Cut at Citi

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

J&J will be separating into two distinct firms, but not right away.

FibroGen Feedback

I continue to get good feedback with regard to FibroGen.   The above is part of a publication on myelodysplastic syndrome.  I would note that Acceleron is being acquired by Merck for $11 billion.  Acceleron has a drug on market which treats 15%-20% ...

Riders on the Storm, More D.C. Nonsense, Early Take on Apple and Amazon

Riders on the Storm, More D.C. Nonsense, Early Take on Apple and Amazon

The two big names disappointed after hours Thursday, but one is more of a concern than the other.

The Worms Turns, O Bank of Canada, Flattening Curve, Ford on Fire, Apple, Amazon

The Worms Turns, O Bank of Canada, Flattening Curve, Ford on Fire, Apple, Amazon

We had almost forgotten that sometimes Mr. Market can still land a ham-sized fist squarely upon that beaming smile of yours.

What a Week, China's Troubles, Hypersonic Weapons, Earnings, FDA Drug Approvals

What a Week, China's Troubles, Hypersonic Weapons, Earnings, FDA Drug Approvals

The lack of urgency at the FDA, as it is in the defense space, is alarming.

Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up

Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up

A recent trio of acquisition deals indicates the doldrums in the sector may be over.

Where the S&P and Nasdaq Stand, The New Green Team, Trading Southwest and Pfizer

Where the S&P and Nasdaq Stand, The New Green Team, Trading Southwest and Pfizer

With earnings season starting in earnest Wednesday, both indexes have offered investors nothing but lower highs coupled with lower lows since the start of September.

Merck Continues to Reward Buyers

Merck Continues to Reward Buyers

Investors are using the available weakness to buy the stock.

The Merck COVID Pill

The reopening trade equities (hotels, airlines, etc.) profited greatly on Friday in large measure because of the Merck  COVID pill announcement.  However, it should be noted that the availability of the pill will be light for months to come.  I have...

Eventually Stocks Will Snap Back

Eventually Stocks Will Snap Back

It is extremely difficult to measure when negative sentiment becomes so extreme that it creates bounce-back conditions, but we are moving in that direction quickly.

Don't Own Merck Stock Yet? Here's My Prescription

Don't Own Merck Stock Yet? Here's My Prescription

I am in this one for the medium to long term.

D.C.'s Not Done Deals, Dissonant Volume, Price Pressures, Real Real Estate Pain

D.C.'s Not Done Deals, Dissonant Volume, Price Pressures, Real Real Estate Pain

Plus, a closer look at a tough Thursday for equities and a rundown on the stocks the author is accumulating.

Serious Thursday, D.C. Dealing, Charting the S&P and Nasdaq, Merck's Antiviral

Serious Thursday, D.C. Dealing, Charting the S&P and Nasdaq, Merck's Antiviral

Is Delta dying down, or is this the calm before the storm up north?

Jim Cramer: The Drug Cos. Are at Full Strength

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.

3 Healthcare Stocks for 3%+ Dividend Yields

3 Healthcare Stocks for 3%+ Dividend Yields

These picks are attractive for value-oriented dividend investors looking for strong current income potential.

A Healthy Outlook for Merck and Its Organon Spinoff

A Healthy Outlook for Merck and Its Organon Spinoff

Organon's management team has deep leadership, operating and financial experience.

What the Fed Said and Did, Robinhood IPO, Trading Ford, Facebook and ServiceNow

What the Fed Said and Did, Robinhood IPO, Trading Ford, Facebook and ServiceNow

Are traders and investors confused? Possibly. Was that the intent? No, but I think Jerome Powell is fine with that.

Happy Thursday Everyone!

Morning folks, once again we've got a slew of earnings reports and at first blush their coming in a tad better than expected from the likes of Nokia , STMicroelectronics , Wolverine World Wide , Textron , Overstock.com  , and Volkswagen (VLKAY). But...

This Retailer Is Marching Toward Kingship

This Retailer Is Marching Toward Kingship

Walgreens Boots Alliance should benefit from an ageing population and increased demand for medications.

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.